Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹22,708 Cr revenue.
COGS 30.1%, employees 17.5%.
“margins have expanded by 750 basis points year over year and 470 basis points quarter over quarter reaching 31.”
“full year EBITDA margins to be in the range of 25 to 26%, higher than our earlier guidance of 24 to 25%.”
“we should be, you know, close to between 275 to $300,000,000 per quarter to close over $1,000,000,000 as we have guided, in the past.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 23.7%▲ | 10.5% |
| ROCE | 27.5%▲ | 13.8% |
| Net Margin | 17.5%▲ | 8.7% |
| EBITDA Margin | 28.6%▲ | 16.0% |
| Debt To Equity | 0.29x▲ | 0.21x |
| Rev Growth 3yr | 11.5%▲ | 5.8% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹26,151 Cr +15.2% | ₹22,708 Cr +13.5% | ₹20,011 Cr +20.2% | ₹16,642 Cr +1.4% | ₹16,405 Cr +8.2% | ₹15,163 Cr -1.4% | ₹15,375 Cr -6.1% | ₹16,369 Cr |
| Other Income | ₹341 Cr +74.0% | ₹196 Cr +63.0% | ₹120 Cr +63.8% | ₹73 Cr -48.2% | ₹142 Cr +4.0% | ₹136 Cr -71.8% | ₹484 Cr -32.1% | ₹713 Cr |
| Total Income | ₹26,491 Cr +15.7% | ₹22,904 Cr +13.8% | ₹20,131 Cr +20.4% | ₹16,715 Cr +1.0% | ₹16,547 Cr +8.2% | ₹15,299 Cr -3.5% | ₹15,859 Cr -7.2% | ₹17,082 Cr |
| COGS | ₹7,161 Cr +4.7% | ₹6,842 Cr +3.0% | ₹6,643 Cr -2.0% | ₹6,780 Cr +4.6% | ₹6,481 Cr +20.9% | ₹5,362 Cr -1.3% | ₹5,431 Cr -7.1% | ₹5,846 Cr |
| ₹20,224 Cr +7.1% | ₹18,889 Cr +6.7% | ₹17,709 Cr +10.7% | ₹15,999 Cr -10.7% | ₹17,920 Cr +31.5% | ₹13,624 Cr -5.1% | ₹14,353 Cr -5.7% | ₹15,229 Cr | |
| Profit Before Tax | ₹5,840 Cr +45.5% | ₹4,015 Cr +65.8% | ₹2,422 Cr +238.1% | ₹716 Cr ↑ Recovery | (₹1,373 Cr) ↓ Decline | ₹1,675 Cr +122.4% | ₹753 Cr -50.3% | ₹1,517 Cr |
| Exceptional Items | (₹427 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹752 Cr) -123.7% | (₹336 Cr) |
| ₹1,171 Cr +65.3% | ₹709 Cr +45.6% | ₹487 Cr +81.1% | ₹269 Cr +96.0% | ₹137 Cr -69.4% | ₹449 Cr -61.2% | ₹1,157 Cr +28.3% | ₹902 Cr | |
| Net Profit | ₹4,669 Cr +41.2% | ₹3,306 Cr +70.8% | ₹1,936 Cr +332.3% | ₹448 Cr ↑ Recovery | (₹1,509 Cr) ↓ Decline | ₹1,228 Cr ↑ Recovery | (₹270 Cr) ↓ Decline | ₹615 Cr |
| Profit (Owners) | ₹4,645 Cr +41.5% | ₹3,282 Cr +71.4% | ₹1,914 Cr +345.1% | ₹430 Cr ↑ Recovery | (₹1,528 Cr) ↓ Decline | ₹1,217 Cr ↑ Recovery | (₹272 Cr) ↓ Decline | ₹607 Cr |
| Minority Interest | ₹24 Cr -1.9% | ₹25 Cr +16.8% | ₹21 Cr +19.8% | ₹18 Cr -5.7% | ₹19 Cr +63.9% | ₹11 Cr +322.2% | ₹3 Cr -69.8% | ₹9 Cr |
| Other Comprehensive Income | ₹399 Cr ↑ Recovery | (₹91 Cr) ↓ Decline | ₹38 Cr +55.2% | ₹24 Cr -76.7% | ₹104 Cr -60.3% | ₹262 Cr ↑ Recovery | (₹608 Cr) -160.1% | (₹234 Cr) |
| EPS | ₹101.70 | ₹71.88 | ₹42.01 | ₹9.45 | (₹33.62) | ₹26.81 | (₹6.02) | ₹13.40 |
| Diluted Shares | ₹46 Cr | ₹46 Cr | ₹46 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Lupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain".
Lupin Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection".
Lupin Limited has informed the Exchange about update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc.
Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026".
Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin s Ankleshwar Facility Receives EIR from U.S. FDA".
Lupin Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension".
Lupin Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026".
Lupin Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi".
Lupin Limited has informed the Exchange regarding Copy of Newspaper Publication regarding Audited Financial Results of the Company for the quarter and year ended March 31, 2026
Lupin Limited has informed the Exchange about Newspaper Publication for the information regarding Special Window for Transfer and Dematerialization of Physical Shares.
Lupin Limited has informed the Exchange regarding a press release dated May 05, 2026, titled "Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid".
Lupin Limited has informed the Exchange regarding Allotment of 36752 Shares.
Lupin Limited has informed the Exchange regarding a press release dated April 22, 2026, titled "Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States".
Lupin Limited has informed the Exchange about U.S. FDA has concluded an inspection at our manufacturing facility located in Somerset, New Jersey, U.S.A.
Lupin Limited has informed the Exchange about execution of Settlement Agreement.